26 Jul Viralgen
Andy Holt, Chief Commercial Officer
Oct. 6 | 2:15pm | FLW Ballroom F
San Sebastian, Spain
(Private)
At Viralgen, we’re all-in on AAV; in fact, that’s all we do. It’s made us a world leader in rAAV-based gene therapy manufacturing, built on a foundation of unmatched expertise and the world’s largest manufacturing capacity dedicated to AAV—and it’s led to a track record that includes more than 30 AAV serotypes, 1,500+ AAV batches and a 100% success rate for IND/IMPD dossiers. Our Aava™ manufacturing platform is a high-performance, real-world-ready solution that can get high-potential gene therapies to market quickly and efficiently at impressive scale, with better predictability and deeper data. We combine this cutting-edge infrastructure with end-to-end support, including plasmid manufacturing, construct optimization, all-inclusive pricing models, and total IP freedom to operate.